Skip to main content

Table 3 Risk factors for nivolumab-induced pneumonitis in patients with solid tumors by univariate and multivariate logistic regression analysis

From: Pre-existing interstitial lung disease is associated with onset of nivolumab-induced pneumonitis in patients with solid tumors: a retrospective analysis

   Univariate model Multivariate model
OR (95% CI) P-value OR (95% CI) P-value
Age, years ≥65 vs. < 65 3.05 (1.08–10.90) 0.034 1.53 (0.44–6.11) 0.51
Sex Male vs. female 10.13 (2.03–183.77) 0.0018 5.58 (1.01–104.40) 0.049
Smoking status Current/ex-smoker vs. Never-smoker 1.52 (0.53–5.50) 0.45    
Performance status ≥2 vs. 0 or 1 0.75 (0.17–2.38) 0.64    
Tumor types NSCLC vs. HNC/GC 1.79 (0.73–4.70) 0.21    
Pre-existing ILD Yes vs. No 9.42 (3.67–25.80) < 0.0001 5.92 (2.07–18.54) 0.0008
NLRa ≥2.5 vs. < 2.5 0.87 (0.35–2.22) 0.76    
  ≥5.0 vs. < 5.0 0.68 (0.21–1.82) 0.45    
LDH (IU/l) ≥240 vs. < 240 1.52 (0.59–3.74) 0.37    
CRP (mg/dl) ≥1 vs. < 1 0.71 (0.27–1.75) 0.46    
  1. Sq squamous cell carcinoma, ILD interstitial lung disease, NLR neutrophil-to-lymphocyte ratio, LDH lactate dehydrogenase, CRP C-reactive protein, OR odds ratio, CI confidence interval
  2. aOne patient with HNC was excluded because NLR was not performed